179 related articles for article (PubMed ID: 34234994)
1. Preclinical development and characterisation of
Wong NC; Cai Y; Meszaros LK; Biersack HJ; Cook GJ; Ting HH; Mottaghy FM
Am J Nucl Med Mol Imaging; 2021; 11(3):154-166. PubMed ID: 34234994
[TBL] [Abstract][Full Text] [Related]
2. Early Phase I Study of a
Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
[TBL] [Abstract][Full Text] [Related]
3. Inter-rater and intra-rater agreement of [
Hughes DJ; Chand G; Johnson J; Bailey D; Adamson K; Goh V; Cook GJR
EJNMMI Res; 2023 May; 13(1):51. PubMed ID: 37256434
[TBL] [Abstract][Full Text] [Related]
4. Inter- and intraobserver agreement of the quantitative assessment of [
Hughes DJ; Chand G; Goh V; Cook GJR
EJNMMI Res; 2020 Dec; 10(1):145. PubMed ID: 33259032
[TBL] [Abstract][Full Text] [Related]
5. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive Imaging of Tumor PD-L1 Expression Using [
Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J
Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699
[TBL] [Abstract][Full Text] [Related]
7. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel
Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and preliminary biological evaluation of a novel
Zhu D; Xu X; Zou P; Liu Y; Wang H; Han G; Lu C; Xie M
Bioorg Med Chem Lett; 2023 Nov; 96():129496. PubMed ID: 37797805
[TBL] [Abstract][Full Text] [Related]
10. [
Nazir MS; Hughes DJ; Chand G; Adamson K; Johnson J; Bailey D; Gibson V; Ting HH; Lyon AR; Cook GJR;
EJNMMI Res; 2023 May; 13(1):44. PubMed ID: 37195370
[TBL] [Abstract][Full Text] [Related]
11. Novel small
Liang Z; Hu X; Hu H; Wang P; Cai J
Front Oncol; 2022; 12():1017737. PubMed ID: 36387113
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Implication of
Gao Y; Luo Q; Sun Z; Gao H; Yu Y; Sun Y; Ma X; Han C; Shi J; Wang F
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36858461
[TBL] [Abstract][Full Text] [Related]
14.
Ferro-Flores G; Ocampo-García B; Cruz-Nova P; Luna-Gutiérrez M; Bravo-Villegas G; Azorín-Vega E; Jiménez-Mancilla N; Michel-Sánchez E; García-Pérez O; Lara-Almazán N; Santos-Cuevas C
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140003
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.
Li F; Cheng T; Dong Q; Wei R; Zhang Z; Luo D; Ma X; Wang S; Gao Q; Ma D; Zhu X; Xi L
Nucl Med Biol; 2015 Mar; 42(3):256-62. PubMed ID: 25516099
[TBL] [Abstract][Full Text] [Related]
16. Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study.
Kurata S; Ushijima K; Kawahara A; Kaida H; Kawano K; Hirose Y; Kage M; Kamura T; Ishibashi M; Abe T
Ann Nucl Med; 2015 Aug; 29(7):643-9. PubMed ID: 25921216
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N
Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.
Kim WH; Kim CG; Kim MH; Kim DW; Park CR; Park JY; Lee YS; Youn H; Kang KW; Jeong JM; Chung JK
Ann Nucl Med; 2016 Jun; 30(5):369-79. PubMed ID: 26993818
[TBL] [Abstract][Full Text] [Related]
19. Investigations of (99m)Tc-labeled glucarate as a SPECT radiotracer for non-small cell lung cancer (NSCLC) and potential tumor uptake mechanism.
Meng L; Xiu Y; Li Y; Xu X; Li S; Li X; Pak KY; Shi H; Cheng D
Nucl Med Biol; 2015 Jul; 42(7):608-13. PubMed ID: 25890861
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]